Association between Serotonin-Related Polymorphisms in 5HT2A, TPH1, TPH2 Genes and Bipolar Disorder in Korean Population

Kwang-Yeon Choi¹
Ho-Kyoung Yoon¹
Yong-Ku Kim¹²

¹Department of Psychiatry, College of Medicine, Korea University, Ansan Hospital, Ansan,
²Division of Brain Korea 21 Biomedical Science, Korea University, Seoul, Korea

Objective The aim of the present study was to examine the association between serotonin-related gene polymorphisms and bipolar disorder in the Korean population. In addition, we sought to explore the relationship between the clinical characteristics of bipolar patients and serotonin-related gene polymorphisms.

Methods Inpatients with bipolar disorder (n=103) and control subjects (n=86) were genotyped for 5HT2A 1438A/G, tryptophan hydroxylase 1 (TPH1) 218 A/C, and TPH2 703G/T. We divided patients with bipolar disorder into two groups according to the presence of psychotic symptoms. The severity of their symptoms was measured using the Young Mania Rating Scale (YMRS) and the Brief Psychiatric Rating Scale (BPRS).

Results There were no significant differences in the genotype distributions or allelic frequencies in the three serotonergic polymorphisms between patients with bipolar disorder and normal controls. There were significant differences in genotype distributions and allele frequencies of the 5-HT2A -1438A/G polymorphism between the psychotic mania group and the non-psychotic mania group (genotype: χ²=7.50, p=0.024; allele: χ²=5.92, p=0.015). However, after Bonferroni correction this significant difference disappeared. We did not find significant differences in the genotype distributions or allelic frequencies in the TPH1 218 A/C and TPH2 703G/T polymorphisms between the psychotic mania group and non-psychotic mania group.

Conclusion We failed to find the statistically significant association between three polymorphisms and bipolar disorder. However, there was a trend towards association between 5-HT2A -1438A/G polymorphism and psychotic symptom in bipolar disorder. Future research should seek to clarify this association.

Key Words Bipolar disorder, Mania, Polymorphism, Serotonin.

Introduction

Bipolar disorder is relatively common psychiatric illness with a lifetime prevalence of 0.5-1.0%.

Disturbance of the serotonergic system has been implicated in the etiology of bipolar disorder. A number of studies of candidate genes involved in serotonin metabolism and serotonergic transmission have been investigated.

The serotonin 2A receptor (5-HT2A) gene is located on chromosome 13q14-q21. It consists of three exons and two introns, spanning over 63 kb. The 1438A/G polymorphism is located on the promoter region of 5-HTR2A, and the 102T/C polymorphism is located on exon 1. The -1438A/G single nucleotide polymorphism (SNP) is in strong linkage disequilibrium with 102T/C SNP. A 1438A/G polymorphism has the potential to modulate 5-HT2A pro-
behavior15,16 and bipolar disorder.17 In a recent meta-analysis, assertions were not replicated in other studies involving suicidalism,13 and aggression-related traits.14 However, such associations with bipolar disorder.6,7 lower than TPH2,19 suggesting that TPH2 may play a much more important role in serotonin synthesis in the brain than TPH1. Consequently, many studies have examined the potential role of TPH2 in the development of depression, suicide,20,21 and bipolar disorder.17 In a recent meta-analysis, the homozygous recessive genotype of the TPH1 A218C polymorphism was reported to increase the risk of bipolar disorder.5 However, other studies have excluded subjects with significant organic brain disease or clinically significant somatic disease. We also collected data such as age of onset, duration of illness, number of illness episodes using medical records and information from relatives because patients in acute manic state could not provide reliable informations on the first day of their admission. The normal control group consisted of healthy individuals who visited Korea University’s Ansan Hospital for regular health screening and volunteered to participate in this study. Participants were excluded if they had a personal or familial psychiatric history, had been diagnosed with a psychiatric illness, or had taken any kind of psychotropic medicines. A total of 86 subjects were recruited. Written informed consent was obtained from all subjects.

We assessed the severity of manic symptoms using the Young Mania Rating Scale (YMRS)26: the severity of psychotic symptoms were assessed using the Brief Psychiatric Rating Scale (BPRS).27 The YMRS and BPRS were administered on the first day after admission. We acquired data on the clinical variables, such as number of episodes and duration of illness. Each case of bipolar disorder was categorized into one of two groups according to the presence of psychotic features. Psychotic features included grandiose delusions, auditory hallucinations, delusions of persecution, and delusions of reference. Patients were categorized in the psychotic mania group if they had any of the psychotic symptoms mentioned above during the index episode.

**Methods**

**Subjects**
A total of 103 bipolar patients were recruited from Korea University’s Ansan Hospital. All subjects were recruited during admission. All patients with bipolar disorder met the DSM-IV criteria29 for bipolar I disorder. Each patient was assessed by trained psychiatrists using a Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I)30 on the first day of their admission. In the case that patient couldn’t cooperate with the interview because of rapid tranquilization we assessed the patient next day or at the latest within 3 days after admission. We excluded subjects with Axis I or II psychiatric comorbidities according to the DSM-IV, such as schizophrenia, alcohol abuse, substance abuse, or personality disorders. We also excluded subjects with significant organic brain disease or clinically significant somatic disease. We also collected data such as age of onset, duration of illness, number of illness episodes using medical records and information from relatives because patients in acute manic state could not provide reliable informations on the first day of their admission. The normal control group consisted of healthy individuals who visited Korea University’s Ansan Hospital for regular health screening and volunteered to participate in this study. Participants were excluded if they had a personal or familial psychiatric history, had been diagnosed with a psychiatric illness, or had taken any kind of psychotropic medicines. A total of 86 subjects were recruited. Written informed consent was obtained from all subjects.

We assessed the severity of manic symptoms using the Young Mania Rating Scale (YMRS)26: the severity of psychotic symptoms were assessed using the Brief Psychiatric Rating Scale (BPRS).27 The YMRS and BPRS were administered on the first day after admission. We acquired data on the clinical variables, such as number of episodes and duration of illness. Each case of bipolar disorder was categorized into one of two groups according to the presence of psychotic features. Psychotic features included grandiose delusions, auditory hallucinations, delusions of persecution, and delusions of reference. Patients were categorized in the psychotic mania group if they had any of the psychotic symptoms mentioned above during the index episode.

**Genotyping**
Deoxyribonucleic acid (DNA) was extracted from plasma leukocytes using the Wizard Genomic DNA Purification Kit (Promega, USA). In order to genotype the 1438A/G SNP in the 5-HT2A gene, a polymerase chain reaction (PCR) was performed with the forward primer 5’-CTGGGTGGCATAGTCTTCTGCT-3’ (-1107 to -1088) and the reverse primer 5’-ACGAGGGACTCCTGTGTTTT-3’ (-1107 to -1088).

The amplification mixture contained 1 μL of 100 ng/μL DNA, 5 μL of 10× PCR buffer, 4 μL of 2.5 mM Ex dNTP mix-
Serotonin Gene and Bipolar Disorder

ture, 2 μL primer, 37.75 μL distilled water, and 0.25 μL Taq polymerase (TaKaRa, Japan). Samples were amplified using a Thermocycler (GeneAmp PCR system 2700, Applied Biosystems, Foster City, CA, USA) for 35 cycles. The thermal cycling conditions were: 94°C for 5 min, followed by 35 cycles of 94°C for 30s, 62°C for 30s, 72°C for 30s, and ending with 72°C for 5 min (GenoAmp PCR system 2700, Applied Biosystems). The amplified DNA was digested with the restriction enzyme MspI (Promega, USA), which cuts at the 1438G sites. The product was electrophoresed on 3% agarose gels and stained with ethidium bromide. Homozygous genotypes were identified by the presence of a single 513-bp band (A/A), or bands of 313- and 182-bp (G/G). The heterozygous genotype (A/G) displayed all three band sizes. In order to genotype the 218A/C SNP in the TPH gene, the reaction mixture consisted of 100 ng of DNA, 2.5 mM Ex dNTP mixture, 5 unit Ex Tag polymerase, 10× Ex Tag buffer (all TaKaRa, Japan), and 10 pmoL of each primer (forward primer: 5′-CGTCCGTGCGCTGTTACT-3′, reverse primer: 5′-CACGCTGCAGTGCCTCAAATC-3′). The thermal cycling conditions were: 94°C for 5 min, followed by 35 cycles of 94°C for 30s, 62°C for 30s, 72°C for 30s, and ending with 72°C for 5 min (GenoAmp PCR system 2700, Applied Biosystems). The product size was 881-bp. After the PCR and digestion by NheI enzyme for 2 h at 37°C, the digested products were analyzed on 2% agarose gel. The TPH C allele was cleaved into fragments of 337- and 544-bp, while the A allele was uncut.

In order to genotype the 703G/T SNP in the TH2 gene, the reaction mixture consisted of 100 ng of DNA, 2.5 mM Ex dNTP mixture, 5 unit Ex Tag polymerase, 10× Ex Tag buffer (all TaKaRa, Japan), and 10 pmoL of each primer (forward primer: 5′-CTGTTATATAACGTTACA-3′, reverse primer: 5′-TCCACTCTCCAGTATTTA-3′). The thermal cycling conditions were: 95°C for 5 min, followed by 35 cycles of 95°C for 30s, 56°C for 30s, 72°C for 30s, and ending with 72°C for 5 min (GenoAmp PCR system 2700, Applied Biosystems). The product size was 881-bp. After the PCR and digestion by NheI enzyme for 2 h at 37°C, the digested products were analyzed on 2% agarose gel. The TPH G allele was uncut.

The presence of Hardy-Weinberg equilibrium was tested by a χ²-test for goodness of fit. Differences in clinical variables (age, age of onset, number of episodes, years of education, and duration of illness) were assessed using t-tests. Differences in genotype and allele frequencies between the bipolar disorder group and the normal control group were evaluated using a χ²-test. In addition, we divided the bipolar disorder group into two groups according to presence of psychotic symptoms. We then used a χ²-test to compare the frequencies of genotype and allele of each subgroup with those of the normal control group. The possibility that the genotypes of the three candidate genes influenced severity of symptom (YMRS, BPRS) and longitudinal course of illness (age of onset, number of episodes) was assessed using one-way analysis of variance (ANOVA). The analysis was performed using Statistical Package for the Social Sciences version 12.0. To consider the multiple comparisons, a Bonferroni correction was applied. Thus the p value for reaching significance is 0.0056 (0.05/9). Post-hoc power analysis using QUANTO 1.2.3 program (http://hydra.usc.edu/gxe) showed that for G allele frequency of 5-HT2A -1438A/G of 0.049, the power was 0.311 [case=103, control=86; α=0.05; odds ratio (OR) of A/G and G/G=1.685; disease frequency=0.01].

Statistical analyses

The presence of Hardy-Weinberg equilibrium was tested by a χ²-test for goodness of fit. Differences in clinical variables (age, age of onset, number of episodes, years of education, and duration of illness) were assessed using t-tests. Differences in genotype and allele frequencies between the bipolar disorder group and the normal control group were evaluated using a χ²-test. In addition, we divided the bipolar disorder group into two groups according to presence of psychotic symptoms. We then used a χ²-test to compare the frequencies of genotype and allele of each subgroup with those of the normal control group. The possibility that the genotypes of the three candidate genes influenced severity of symptom (YMRS, BPRS) and longitudinal course of illness (age of onset, number of episodes) was assessed using one-way analysis of variance (ANOVA). The analysis was performed using Statistical Package for the Social Sciences version 12.0. To consider the multiple comparisons, a Bonferroni correction was applied. Thus the p value for reaching significance is 0.0056 (0.05/9). Post-hoc power analysis using QUANTO 1.2.3 program (http://hydra.usc.edu/gxe) showed that for G allele frequency of 5-HT2A -1438A/G of 0.049, the power was 0.311 [case=103, control=86; α=0.05; odds ratio (OR) of A/G and G/G=1.685; disease frequency=0.01].

### Table 1. Symptom and characteristic comparison between controls and patients with bipolar disorder

| Characteristic                  | Comparison subjects (N=86) | Patients with bipolar disorder | Analysis |
|--------------------------------|-----------------------------|--------------------------------|----------|
|                                | Mean±SD                     | Mean±SD                        | t        | p        |
| Age at interview               | 31.2±9.7                    | 33.7±10.6                      | 0.14     | 0.89†    |
|                                | 33.6±10.2                   | 34.0±11.9                      |          |          |
| Age of onset                   | 29.7±10.7                   | 29.7±10.6                      | 0.09     | 0.93‡    |
|                                | 30.0±11.4                   | 2.13±1.36                      | 0.40     | 0.69Δ    |
| No. of episodes                | 1.99±1.9                    | 1.94±2.07                      | 0.02     | 0.99‡    |
| Years of education             | 12.2±2.6                    | 12.2±2.7                       | 0.02     | 0.99‡    |
| Duration of illness            | 49.6±65.2                   | 51.0±68.7                      | 0.40     | 0.69Δ    |
| Baseline YMRS                  | 33.5±9.5                    | 34.0±9.0                       | 0.89     | 0.37‡    |
| Baseline BPRS                  | 21.2±8.7                    | 22.6±8.1                       | 2.82     | 0.006*‡  |
|                                | N %                         | N %                            |          |          |
| Female (sex)                   | 35 40.7                     | 57 55.3                        |          |          |

*p<0.05, †-test between comparison subjects and patients with bipolar disorder. ‡-test between patients with psychotic features and patients without psychotic features. SD: standard deviation, YMRS: Young Mania Rating Scale, BPRS: Brief Psychiatric Rating Scale

62 Psychiatry Investig 2010;7:60-67
Results

Characteristics of the subjects

There were no differences in age or gender distribution between the bipolar patient group and the control group (Table 1). There were no significant difference in age of onset, number of episodes, years of education, duration of illness, or baseline YMRS score between the psychotic mania group and the non-psychotic mania group. However, the psychotic mania group had significantly higher BPRS scores than the non-psychotic mania group (psychotic mania group: 22.6±8.7; non-psychotic mania: 16.6±9.2).

Genotype and allele frequencies of the three polymorphisms in the control and bipolar disorder groups

The distribution of the 5-HTR2A 1438A/G, TPH 218A/C, and TPH2 703G/T polymorphisms in bipolar patients and controls were in agreement with Hardy-Weinberg equilibrium. There were no significant statistical differences in the genotype distributions or allele frequencies of the three tested polymorphisms between the bipolar disorder group and the control group (Table 2).

Genotype and allele frequencies of the three polymorphisms in the psychotic mania group and non-psychotic mania group

Post-hoc tests did reveal differences in genotype distributions and allele frequencies of 5-HT2A -1438A/G polymorphism between the psychotic mania group and the non-psychotic mania group (Table 3). Moreover, there was a significant difference when we categorized genotype into two groups according to the presence of allele G (AA vs. AG+GG, χ²=6.83, p=0.009)(Table 4). However, after applying the Bonferroni correction, significance dissipated.

---

Table 2. Genotype and allele frequencies in controls and patients with bipolar disorder

| 5-HT2A receptor gene promoter -1438A/G | Genotype | Analysis | Allele | Analysis |
|----------------------------------------|----------|----------|--------|----------|
|                                        | A/A | A/G | G/G | χ² (df=2) | p | A | G | χ² (df=1) | p |
| Comparison subjects (N=86)             | 27  | 38  | 21  | 3.01  | 0.223 | 92 | 80 | 0.75  | 0.388 |
| Patients with bipolar disorder         |      |     |     |        |      |    |     |       |        |
| All patients (N=103)                   | 22  | 57  | 24  | 3.01  | 0.223 | 101| 105|       |        |
| Patients with psychotic                | 21.3%| 55.3%| 23.3%| 3.01  | 0.223 | 49.0%| 51.0%|       |        |
| Features (N=78)                        | 12  | 45  | 21  | 7.50  | 0.024*| 69 | 87 | 5.92  | 0.015*|
| Patients without psychotic             | 15.4%| 57.7%| 26.9%| 7.50  | 0.024*| 44.2%| 55.8%|       |        |
| Features (N=25)                        | 40.0%| 48.0%| 12.0%| 7.50  | 0.024*| 64.0%| 56.0%|       |        |
| TPH1 gene promoter -218A/C             | A/A | A/C | C/C | χ² (df=2) | p | A | C | χ² (df=1) | p |
| Comparison subjects (N=86)             | 28  | 39  | 19  | 0.187 | 0.911 | 95 | 77 | 0.203 | 0.652 |
| Patients with bipolar disorder         |      |     |     |        |      |    |     |       |        |
| All patients (N=103)                   | 31  | 47  | 25  | 0.187 | 0.911 | 109| 97 |       |        |
| Patients with psychotic                | 32.6%| 45.3%| 22.1%| 0.187 | 0.911 | 55.2%| 44.8%|       |        |
| Features (N=78)                        | 31  | 47  | 25  | 0.187 | 0.911 | 109| 97 |       |        |
| Patients without psychotic             | 30.1%| 45.6%| 24.3%| 0.187 | 0.911 | 52.9%| 47.1%|       |        |
| Features (N=25)                        | 26  | 36  | 16  | 3.01  | 0.022 | 88 | 68 | 3.16  | 0.076 |
| TPH2 gene promoter -703G/T             | G/G | G/T | T/T | χ² (df=2) | p | G | T | χ² (df=1) | p |
| Comparison subjects (N=86)             | 17  | 40  | 29  | 1.48  | 0.477 | 74 | 98 | 0.782 | 0.376 |
| Patients with bipolar disorder         |      |     |     |        |      |    |     |       |        |
| All patients (N=103)                   | 28  | 42  | 33  | 0.187 | 0.911 | 98 | 108|       |        |
| Patients with psychotic                | 8.1% | 46.5%| 33.7%| 0.187 | 0.911 | 43.0%| 57.0%|       |        |
| Features (N=78)                        | 28  | 42  | 33  | 0.187 | 0.911 | 98 | 108|       |        |
| Patients without psychotic             | 27.2%| 40.8%| 30.0%| 0.187 | 0.911 | 47.6%| 52.4%|       |        |
| Features (N=25)                        | 22  | 31  | 25  | 2.07  | 0.005 | 75 | 81 | 0.065 | 0.798 |

*p<0.05, after Bonferroni correction significance dissipated. TPH: tryptophan hydroxylase
ferroni correction, the difference in genotype distributions disappeared ($\alpha=0.0056$). No differences in either genotype distribution or allele frequencies of TPH1 -218A/C and TPH2 -703G/T between the psychotic mania group and the non-psychotic mania group were observed.

Comparison of the characteristics of bipolar disorder according to the three polymorphisms

Symptom severity differences among the genotypes were also compared (Table 5). For the three gene polymorphisms, there were no significant differences in baseline BPRS, YMRS, age of onset, or number of episodes.

Discussion

We hypothesized that serotonin-related gene polymorphisms might affect the appearance of psychotic features in patients with bipolar disorder. Even though we failed to show a statistically significant result, the present study suggested that the 5-HT2A receptor gene promoter -1438A/G polymorphism might be associated with the presence of psychotic features in patients with bipolar disorder. Our result suggested that presence of the G allele could be associated with psychotic feature in bipolar disorder.

There is some evidence that the 5-HT2A receptor affects the psychotic symptoms in psychiatric disorders. However, the relationship between the 5-HT2A receptor and affective disorders with psychotic features has not been investigated. In schizophrenia, activation of 5-HT2A receptors in the prefrontal cortex may contribute to psychotic symptoms by enhancing the excitation of the descending glutamate neuron, which excites the mesolimbic dopamine neuron it innervates downstream.\textsuperscript{28,29} Both N-methyl-D-aspartate antagonist state (ketamine) and 5-HT2A agonist state (N,N-dimethyltryptamine, DMT) have been suggested as an appropriate model for psychosis. However, the two models have a difference in symptomatology. In the DMT model, positive symptoms are almost more prominent than negative symptoms. In the ketamine model for schizophrenia, on the other hand, phenomena that resemble cognitive symptoms, negative symptoms, and catatonic symptoms of schizophrenia were more prominent than they were in the DMT model for schizophrenia.\textsuperscript{30} We could therefore argue that the 5-HT2A agonist model is more apt for explaining the psychotic features in bipolar disorder. In order to explain the results of our study, we could assume that 5-HT2A promoter -1438A/G polymorphism affected the promoter activity or expression of the 5-HT2A receptor during manic episodes. In detail, allele -G at 5-HT2A gene promoter

---

**Table 3.** Genotype and allele frequencies in psychotic bipolar disorder group and non-psychotic bipolar disorder group, according to 5-HT2A 1438A/G polymorphism

| 5-HT2A receptor gene promoter -1438A/G | Genotype | Allele |
|----------------------------------------|----------|--------|
|                                        | A/A      | A/G    | G/G    | A    | G    |
| Comparison subjects (N=86)             | 27       | 38     | 21     | 92   | 80   |
|                                       | 21.3%    | 55.3%  | 23.3%  | 49.0%| 51.0%|
| Patients with psychotic features (N=78)| 12       | 45     | 21     | 69   | 87   |
|                                       | 15.4%    | 57.7%  | 26.9%  | 44.2%| 55.8%|
| Patients without psychotic features (N=25)| 10      | 12     | 3      | 32   | 18   |
|                                       | 40.0%    | 48.0%  | 12.0%  | 64.0%| 36.0%|

| C vs. P+N                               | 9.55     | 0.049  |
| C vs. P                                 | 5.98     | 0.050  |
| C vs. N                                 | 1.87     | 0.392  |
| P vs. N                                 | 7.50     | 0.024* |

*p<0.05, but after Bonferroni correction significance dissapeared. C: comparison subjects, P: patients with psychotic features, N: Patients without psychotic features

**Table 4.** Odds ratio for having psychotic features in patients with bipolar disorder

| 5-HT2A -1438A/G | Psychotic mania | Nonpsychotic mania | OR  | 95% CI   | $\chi^2$ | p   |
|-----------------|-----------------|--------------------|-----|----------|---------|-----|
| A/A             | 12              | 10                 | 1.00| NA       |
| A/G             | 45              | 12                 | 3.13| 1.09-8.96|         |
| G/G             | 21              | 3                  | 5.83| 1.34-25.43|
| A/G+G/G         | 66              | 15                 | 3.66| 1.33-10.10| 6.83    | 0.009*|

*p<0.05, but after Bonferroni correction significance dissapeared, \(^*\) $\chi^2$ test between A/A and A/G+G/G. NA: not applicable, OR: odds ratio, CI: confidence interval
Table 5. Comparison of clinical variables in bipolar disorder

| 5-HT2A receptor gene promoter -1438A/G | Genotype | ANOVA |
|---------------------------------------|----------|-------|
| Age of onset                          |          |       |
| A/A                                   | 26.4±8.8 |       |
| A/G                                   | 31.2±11.6|       |
| G/G                                   | 29.3±9.9 |       |
| F                                     | 1.517    | 0.225 |
| p                                     |          |       |
| No. of episode                        |          |       |
| A/A                                   | 2.0±1.9  |       |
| A/G                                   | 2.3±2.1  |       |
| G/G                                   | 1.4±1.5  |       |
| F                                     | 1.564    | 0.215 |
| p                                     |          |       |
| Baseline YMRS                         |          |       |
| A/A                                   | 37.3±11.6|       |
| A/G                                   | 33.3±8.2 |       |
| G/G                                   | 30.3±9.2 |       |
| F                                     | 2.869    | 0.062 |
| p                                     |          |       |
| Baseline BPRS                         |          |       |
| A/A                                   | 22.4±10.9|       |
| A/G                                   | 21.6±8.1 |       |
| G/G                                   | 19.1±7.8 |       |
| F                                     | 0.826    | 0.442 |
| p                                     |          |       |

| TPH1 gene promoter-218A/C | Genotype | ANOVA |
|--------------------------|----------|-------|
| Age of onset             |          |       |
| A/A                      | 31.7±11.5|       |
| A/C                      | 30.4±11.2|       |
| C/C                      | 25.3±7.1 |       |
| F                        | 2.402    | 0.096 |
| p                        |          |       |
| No. of episode           |          |       |
| A/A                      | 1.8±1.7  |       |
| A/C                      | 2.1±2.0  |       |
| C/C                      | 2.0±2.2  |       |
| F                        | 0.212    | 0.810 |
| p                        |          |       |
| Baseline YMRS            |          |       |
| A/A                      | 34.0±11.0|       |
| A/C                      | 33.5±7.9 |       |
| C/C                      | 32.7±10.6|       |
| F                        | 0.110    | 0.896 |
| p                        |          |       |
| Baseline BPRS            |          |       |
| A/A                      | 21.1±8.3 |       |
| A/C                      | 22.4±7.5 |       |
| C/C                      | 18.7±11.3|       |
| F                        | 1.134    | 0.327 |
| p                        |          |       |

| TPH2 gene promoter-703G/T | Genotype | ANOVA |
|--------------------------|----------|-------|
| Age of onset             |          |       |
| G/G                      | 29.1±10.5|       |
| G/T                      | 30.9±12.0|       |
| T/T                      | 28.6±9.2 |       |
| F                        | 0.447    | 0.641 |
| p                        |          |       |
| No. of episode           |          |       |
| G/G                      | 1.6±1.8  |       |
| G/T                      | 2.0±1.8  |       |
| T/T                      | 2.3±2.2  |       |
| F                        | 0.827    | 0.440 |
| p                        |          |       |
| Baseline YMRS            |          |       |
| G/G                      | 33.3±10.4|       |
| G/T                      | 32.9±9.7 |       |
| T/T                      | 34.5±8.6 |       |
| F                        | 0.250    | 0.780 |
| p                        |          |       |
| Baseline BPRS            |          |       |
| G/G                      | 23.9±10.1|       |
| G/T                      | 20.7±8.4 |       |
| T/T                      | 19.9±7.9 |       |
| F                        | 1.305    | 0.277 |
| p                        |          |       |

YMRS: Young Mania Rating Scale, BPRS: Brief Psychiatric Rating Scale, ANOVA: analysis of variance

-1438 may have increased the expression of 5-HT2A receptors during manic episodes, thereby predisposing the 5-HT2A agonist state that produced the psychotic features. However, previous studies investigating the promoter activity of the 5-HT2A-1438A/G polymorphism did not support this hypothesis. Spurlock et al.31 reported that there was no functional difference between allele A and allele G at 1438 locus in promoter activity. Yet in 2002, Myers et al.32 demonstrated that in vitro assays showed neither A- nor G-allele of -1438 locus had significant effects on promoter activity when expressed with the major alleles at 1420C/T and -783A/G. However, promoter activity was decreased significantly when minor allele G at 783 was expressed with G- allele at -1438.

Another possible explanation is that the decreased activity of the 5-HT2A receptor, due to the polymorphism of the 5-HT2A receptor gene, affects the 5HT2A-dopamine interaction to decrease the ability to stabilize the dopamine activity. Activation of the 5-HT2A receptor decreases the activity of dopaminergic neurons in the ventral tegmental area via gamma-aminobutyric acid interneurons.33 The psychotic manic state is supposed to be a hyperdopaminergic state. If the polymorphism in the 5-HT2A gene decreased the activity of 5-HT2A, it would become the vulnerable gene for psychosis.

We simultaneously investigated the association between three serotonin-related gene polymorphisms and bipolar disorder. To our knowledge, this is the first association study between TPH2 -703T polymorphisms and bipolar disorder in the Korean population. We found no association between TPH2 and bipolar disorder.

An example of gene-gene interaction was recently reported when Lin et al.34 demonstrated that TPH1 interacts with TPH2 to modify the risk for bipolar disorder. Those with the TPH2 at-risk TAG haplotype have the OR of 3.73 for developing bipolar disorder. Yet, if combined with TPH1 -346G allele or TPH1 -346T, the odds ratio for bipolar disorder becomes 4.81 or 1.68, respectively.34 The presence of gene-gene interaction may explain why the results of association studies are inconsistent. In the future, efforts directed toward finding both gene-gene interactions and candidate genes for bipolar disorder are necessary.

A recent meta-analysis suggested that the homozygous genotype of the TPH A218C polymorphism may increase the risk for bipolar disorder.3 However, our study also suggested that the TPH1 A218C polymorphism was not associated with bipolar disorder. In 2001, Oh et al.35 investigated the association between the 5-HT2A receptor gene promoter -1438A/G polymorphism and bipolar disorder in the Korean population. They suggested that the A allele is significantly more frequent in patients suffering from affective episodes and the duration of illness. It is worth noting the weaknesses of the present study. First, we interviewed the patients and their first-degree relatives during their admissions and collected information about past history of affective episodes and the duration of illness. Consequently, we could not control recall bias. During manic
episodes, patients and their families tended to remember previous manic episodes more than depressive episodes, possibly causing the number of depressive episodes to be underestimated. Second, the relatively small sample size limited the power of investigating the possible associations between the above serotonin-related gene polymorphisms and bipolar disorder.

In conclusion, we failed to found the statistically significant association between three polymorphisms and bipolar disorder. However, there was a trend towards association between 5-HT2A -1438A/G polymorphism and psychotic symptoms in bipolar disorder. In future studies, large sample sizes should be used to confirm our results.

Acknowledgments

This study was supported by a grant from the Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (A040042). This paper was done as part of the master’s thesis (in medicine) of Dr. K-Y Choi.

REFERENCES

1. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, et al. Lifetime and 12-month prevalence of bipolar disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007;64:543-552.

2. McGuffin P, Rijsdijk F, Andrew M, Sham P, Katz R, Cardno A. The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch Gen Psychiatry 2003;60:497-502.

3. Arranz MJ, Munro J, Owen MJ, Spurlock G, Zhao J, et al. Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clonazep.

4. Parsons MJ, D’Souza UM, Arranz MJ, Kerwin RW, Makoff AJ. The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. Biol Psychiatry 2004;56:406-410.

5. Chee IS, Lee SW, Kim JL, Wang SK, Shin YO, Shin SC, et al. 5-HT2A receptor gene polymorphism -1438A/G and bipolar disorder. Psychi.

6. Ohara K, Nagai M, Tsukamoto T, Tani K, Suzuki Y. 5-HT2A receptor gene promoter polymorphism -1438A/G and bipolar disorder. Psychiatr Genet 2001;11:111-114.

7. Etain B, Rousseva A, Roy I, Henry C, Malafosse A, Buresi C, et al. Lack of association between 5-HT2A receptor gene haplotype, bipolar disorder and its clinical subtypes in a West European sample. Am J Med Genet B Neuropsychiatr Genet 2004;129B:29-33.

8. Zhang HY, Ishigaki T, Tani K, Chen K, Shih JC, Miyasato K, et al. Serotonin2A receptor gene polymorphism in mood disorders. Biol Psychiatry 1997;41:768-773.

9. Jequier E, Robinson DS, Lovenberg W, Sjoerdsma A. Further studies on tryptophan hydroxylase in rat brainstem and beef pineal. Biochem Pharmacol 1969;18:1071-1081.

10. Patel PD, Pontrello C, Burke S. Robust and tissue-specific expression of TPH2 versus TPH1 in rat raphe and pineal gland. Biol Psychiatry 2004;55:428-433.

11. Walther DJ, Bader M. A unique central tryptophan hydroxylase iso.

12. Bellivier F, Leboyer M, Courtet P, Buresi C, Beaufils B, Samolyk D, et al. Association between the tryptophan hydroxylase gene and maniac-depressive illness. Arch Gen Psychiatry 1998;55:33-37.

13. Nielsen DA, Virkunen M, Lappalainen J, Eggert M, Brown GL, Long JC, et al. A tryptophan hydroxylase gene marker for suicidality and alcoholism. Arch Gen Psychiatry 1998;55:593-602.

14. Manuck SB, Flory JD, Ferrell RE, Dent KM, Mann JJ, Muldoon MF. Aggression and anger-related traits associated with a polymorphism of the tryptophan hydroxylase gene. Biol Psychiatry 1999;45:603-614.

15. Yoon HK, Kim YK. Association between serotonin-related gene poly.

16. Lalovic A, Turecki G. Meta-analysis of the association between tryptophan hydroxylase and suicidal behavior. Am J Med Genet 2002;114:533-540.

17. Lai TJ, Wu CY, Tsai HW, Lin YM, Sun HS. Polymorphism screening and haplotype analysis of the tryptophan hydroxylase gene (TPH1) and association with bipolar affective disorder in Taiwan. BMC Med Genet 2005;6:14.

18. Chen C, Glatt SJ, Tsuang MT. The tryptophan hydroxylase gene influences risk for bipolar disorder but not major depressive disorder: results of meta-analyses. Bipolar Disord 2008;10:816-821.

19. Walther DJ, Peter JU, Bashamnakh S, Hörttagl H, Voits M, Fink H, et al. Synthesis of serotonin by a second tryptophan hydroxylase iso.

20. Yoon HK, Kim YK. TPH2 -703G/T SNP may have important effect on susceptibility to suicidal behavior in major depression. Prog Neu.

21. Lopez VA, Detera-Wadleigh S, Cardona I, Kassem L, McMahon FJ. Nested association between genetic variation in tryptophan hydroxylase II, bipolar affective disorder, and suicide attempts. Biol Psychiatry 2007;61:181-186.

22. Grigorou-Serbanescu M, Diaconu CC, Hermes S, Bleotu C, Vollmer J, Muhleisen TW, et al. Investigation of the tryptophan hydroxylase 2 gene in bipolar disorder in the Romanian population. Psychiatr Genet 2008;18:240-247.

23. De Luca V, Likhodi O, Van Tol HH, Kennedy JL, Wong AH. Tryptophan hydroxylase 2 gene expression and promoter polymorphisms in bipolar disorder and schizophrenia. Psychopharmacology (Berl) 2005;183:378-382.

24. APA (American Psychological Association). Diagnostic and statistical manual of mental disorders, 4th edition. Washington DC: American Psychiatric Press; 1994.

25. First M, Spitzer RL, Gibbon M, William JB. Structured clinical Interview for DSM-IV Axis I Disorder-Patient Edition (SCID-I/NP, version 2.0), New York: Biometrics Research Department, New York State Psychiatric Institute: 1998.

26. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability and validity. Br J Psychiatry 1978;133:429-435.

27. Beck P, Larsen JK, Andersen J. The BRPS: psychometric developments. Psychopharmacol Bull 1988;24:118-121.

28. Stahl SM. Stahl’s essential psychopharmacology, neuroscience basis and practical applications. 3rd edition. New York: Cambridge U.P. 2008, p.359-361.

29. Glenthoj BY, Mackeprang T, Svarer C, Rasmussen H, Pinborg LH, Friberg L, et al. Frontal dopamine D(2/3) receptor binding in drug-naive first-episode schizophrenic patients correlates with positive psychotic symptoms and gender. Biol Psychiatry 2006;66:621-629.

30. Gozoulis-Mayfrank E, Heekeren K, Neukirch A, Stock C, Turecki G. Aggression and anger-related traits associated with a polymorphism in the promoter region of the human serotonin 5-HT2A receptor gene (HTR2A) influence gene expression. Biol Psychiatry 2007;61:167-173.

66 Psychiatry Investig 2010;7:60-67
33. Stahl SM. Stahl's essential psychopharmacology-neuroscientific basis and practical application. 3rd edition. Cambridge. 2008, p.484.
34. Lin YM, Chao SC, Chen TM, Lai TJ, Chen JS, Sun HS. Association of functional polymorphisms of the human tryptophan hydroxylase 2 gene with risk for bipolar disorder in Han Chinese. Arch Gen Psychiatry 2007;64:1015-1024.
35. Oh SY, Chee IS, Lee YH. Association between 5-HT2A receptor gene promoter -1438A/G polymorphism and bipolar disorder in a Korean population Korean Neuropsychiatric Association 2001;40:81-86.